2016
Tetsu O, Hangauer MJ, Phuchareon J, Eisele DW, McCormick F.2016 Drug Resistance to EGFR Inhibitors in Lung Cancer.Chemotherapy. 2016 Feb 25;61(5):223-235. [Epub ahead of print]
2015
Tetsu O, Phuchareon J, Eisele DW, Hangauer MJ, McCormick F. 2015 AKT inactivation causes persistent drug tolerance to EGFR inhibitors. Pharmacol Res. 102:132-7. doi: 10.1016/j.phrs.2015.09.022. Epub 2015 Oct 22.
Wang, M.T., Holderfield, M., Galeas, J., Delrosario, R., To, M.D., Balmain, A., McCormick. F. 2015. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163 :1237-51. doi: 10.1016/j.cell.2015.10.041.
Gillette WK, Esposito D, Abreu Blanco M, Alexander P, Bindu L, Bittner C, Chertov O, Frank PH, Grose C, Jones JE, Meng Z, Perkins S, Van Q, Ghirlando R, Fivash M, Nissley DV, McCormick F, Holderfield M, Stephen AG. 2015. Farnesylated and methylated KRAS4b: high yield production of protein suitable for biophysical studies of prenylated protein-lipid interactions. Sci Rep. 5:15916. doi: 10.1038/srep15916.
Tetsu, O., Eisele, D.W., McCormick, F. 2015. Resistance to EGFR-targeted by Ets-1 inactivation. Cell Cycle 14:3211-2. doi: 10.1080/15384101.2015.1086200. No abstract available.
Phuchareon, J., McCormick, F., Eisele, D.W., Tetsu, O. 2015. EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function. Proc Natl Acad Sci U S A 112:E3855-63 doi: 10.1073/pnas.1510733112. Epub 2015 Jul 6.
Nan, X., Tamgüney, T.M., Collisson, E.A., Lin, L.J., Pitt, C., Galeas, J., Lewis, S., Gray, J.W., McCormick, F., Chu, S. 2015. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK). Proc Natl Acad Sci U S A 112:7996-8001 doi: 10.1073/pnas.1509123112. Epub 2015 Jun 16.
Fujita-Sato, S., Galeas, J., Truitt, M., Pitt, C., Urisman, A., Bandyopadhyay, S., Ruggero, D., McCormick, F. 2015. Enhanced MET translation and signaling sustains K-Ras driven proliferation under anchorage-independent growth conditions. Cancer Res 75:2851-62 doi: 10.1158/0008-5472.CAN-14-1623. Epub 2015 May 14
McCormick, F. 2015. KRAS as a therapeutic target. Clin Cancer Res 21:1797-801.
McCormick, F. 2015. The potential of targeting Ras proteins in lung cancer. Expert Opin Ther Targets Jan 6:1-4
2014
Martins, M.M., Zhou, A.Y., Corella, A., Horiuchi, D., Yau, C., Rakshandehroo, T., Gordan, J.D., Levin, R.S., Johnson, J., Jascur, J., Shales, M., Sorrentino, A., Cheah, J., Clemons, P.A., Shamji, A.F., Schreiber, S.L., Krogan, N.,J., Shokat, K.M., McCormick, F., Goga, A., Bandyopadhyay, S. 2015. Linking Tumor Mutations to Drug Responses via a Quantitative Chemical-Genetic Interaction Map. Cancer Discov 5:154-67 doi: 10.1158/2159-8290.CD-14-0552. Epub 2014 Dec 12
